Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Venglustat in Fabry Disease with Left Ventricular Hypertrophy
NCT05280548Phase 3Active, not recruiting
- Sponsor
- Sanofi
- Start
- May 2022
- Primary completion
- May 2026
- Modality
- Small Molecules
- Countries
- 19
01
Overview
A Phase 3 trial of venglustat in Fabry disease (FD), sponsored by Sanofi. Started May 2022; status: active, not recruiting.
02
Drugs
venglustat
03
Conditions
Fabry disease (FD)
Beyond the preview
Go deeper on NCT05280548.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05280548.